Volume 13, Number 12—December 2007
Dispatch
Risk Factors for West Nile Virus Neuroinvasive Disease, California, 2005
Table 1
Characteristic | WNND, no./total (%) | WNF, no./total (%) | 95% Confidence interval | p value† |
---|---|---|---|---|
Sex, M | 188/305 (62) | 270/534 (51) | 1.18–2.09 | <0.01 |
Age, y | ||||
<18 | 12/305 (4) | 19/534 (4) | 0.53–2.32 | 0.85 |
18–44 | 73/305 (24) | 180/534 (34) | 0.45–0.85 | <0.01 |
45–64 | 121/305 (40) | 240/534 (45) | 0.61–1.07 | 0.15 |
65–74 | 51/305 (17) | 61/534 (11) | 1.09–2.33 | 0.03 |
>75 |
48/305 (16) |
33/534 (6) |
1.78–4.53 |
<0.0001 |
Symptom | ||||
Fever | 254/283 (90) | 315/456 (69) | 2.54–6.04 | <0.0001 |
Headache | 202/262 (77) | 387/483 (80) | 0.58–1.20 | 0.33 |
Rash | 54/244 (22) | 239/469 (51) | 0.19–0.39 | <0.0001 |
Muscle pain/weakness | 215/274 (78) | 393/485 (81) | 0.59–1.23 | 0.40 |
Seizures | 11/153 (7) | 2/313 (0.6) | 2.64–55.06 | 0.001 |
Altered mental status | 148/275 (54) | 68/463 (15) | 4.77–9.61 | <0.0001 |
*WNV, West Nile virus; WNND, West Nile neuroinvasive disease; WNF, West Nile fever.
†Fisher exact test, 2-tailed.
Page created: July 06, 2010
Page updated: July 06, 2010
Page reviewed: July 06, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.